Comparison between Bombay Super Hybrid Seeds IPO and Indo US Bio-Tech IPO.
IPO Details
Bombay Super Hybrid Seeds IPO is a SME Fixed Price IPO proposed to list at NSE SME while Indo US Bio-Tech IPO is a SME Fixed Price proposed to list at BSE SME.
Issue Size and Price
The total issue size of Bombay Super Hybrid Seeds IPO is up to ₹9.86 Cr whereas the issue size of the Indo US Bio-Tech IPO is up to ₹6.92 Cr. The final issue price of Bombay Super Hybrid Seeds IPO is ₹60.00 per share and of Indo US Bio-Tech IPO is ₹51.00 per share.
IPO Timetable
Bombay Super Hybrid Seeds IPO opens on Apr 12, 2018, while Indo US Bio-Tech IPO opens on Apr 30, 2018. The closing date of Bombay Super Hybrid Seeds IPO and Indo US Bio-Tech IPO is Apr 17, 2018, and May 03, 2018, respectively.
| | Bombay Super Hybrid Seeds IPO | Indo US Bio-Tech IPO |
|---|
| Issue Open | Apr 12, 2018 | Apr 30, 2018 |
| Issue Close | Apr 17, 2018 | May 03, 2018 |
| Basis Of Allotment (Tentative) | Apr 20, 2018 | May 08, 2018 |
| Initiation of Refunds (Tentative) | Apr 23, 2018 | |
| Credit of Share (Tentative) | Apr 24, 2018 | |
| Listing date (Tentative) | Apr 25, 2018 | May 11, 2018 |
Financials & KPIs
Bombay Super Hybrid Seeds IPO P/E ratio is , as compared to Indo US Bio-Tech IPO P/E ratio of .
Shares Offered
In the Bombay Super Hybrid Seeds IPO Retail Individual Investors (RII) are offered 8,22,000 shares while in Indo US Bio-Tech IPO retail investors are offered 8,22,000 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Bombay Super Hybrid Seeds IPO and 0 shares in Indo US Bio-Tech IPO.
| | Bombay Super Hybrid Seeds IPO | Indo US Bio-Tech IPO |
|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 88,000 shares | 74,000 shares |
| QIB | 0 shares | 0 shares |
| NII | 8,22,000 shares | 6,78,000 shares |
| RII | 8,22,000 shares | 6,78,000 shares |
| Employee | 0 shares | 0 shares |
| Total | 16,44,000 shares | 13,56,000 shares |
Bids Received (Subscription)
Bombay Super Hybrid Seeds IPO subscribed 9.50x in total, whereas Indo US Bio-Tech IPO subscribed 19.69x.
